Organization and Description of the Business (Details)	12 Months Ended
	Dec. 31, 2015 USD ($) item shares	Dec. 31, 2014 USD ($) shares
Liquidity
Revenues	$ 0
Number of dose forms for modulator | item	3
Accumulated deficit	$ (97,186,000)	$ (72,336,000)
Aggregate net proceeds from initial public offering	$ 28,278,000	$ 41,202,000
Common Stock
Liquidity
Stock Issued During Period, Shares, New Issues | shares	5,056,003	5,758,000